tetano
Editor, Senior Moderator
Vaccine
. 2023 Sep 20;S0264-410X(23)00871-X.
doi: 10.1016/j.vaccine.2023.07.040. Online ahead of print. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Bethanie Wilkinson[SUP] 1 [/SUP], Kinjal S Patel[SUP] 1 [/SUP], Katherine Smith[SUP] 1 [/SUP], Robert Walker[SUP] 1 [/SUP], Chengbin Wang[SUP] 1 [/SUP], Ann M Greene[SUP] 1 [/SUP], Gale Smith[SUP] 1 [/SUP], Emily R Smith[SUP] 2 [/SUP], Marc Gurwith[SUP] 3 [/SUP], Robert T Chen[SUP] 3 [/SUP]; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG)
Affiliations
Novavax, a global vaccine company, began evaluating NVX-CoV2373 in human studies in May 2020 and the pivotal placebo-controlled phase 3 studies started in November 2020; five clinical studies provided adult and adolescent clinical data for over 31,000 participants who were administered NVX-CoV2373. This extensive data has demonstrated a well-tolerated response to NVX-CoV2373 and high vaccine efficacy against mild, moderate, or severe COVID-19 using a two-dose series (Dunkle et al., 2022) [1], (Heath et al., 2021) [2], (Keech et al., 2020) [3], (Mallory et al., 2022) [4]. The most common adverse events seen after administration with NVX-CoV2373 were injection site tenderness, injection site pain, fatigue, myalgia, headache, malaise, arthralgia, nausea, or vomiting. In addition, immunogenicity against variants of interest (VOI) and variants of concern (VOC) was established with high titers of ACE2 receptor-inhibiting and neutralizing antibodies in these studies (EMA, 2022) [5], (FDA, 2023) [6]. Further studies on correlates of protection determined that titers of anti-Spike IgG and neutralizing antibodies correlated with efficacy against symptomatic COVID-19 established in clinical trials (p < 0.001 for recombinant protein vaccine and p = 0.005 for mRNA vaccines for IgG levels) (Fong et al., 2022) [7]. Administration of a booster dose of the recombinant protein vaccine approximately 6 months following the primary two-dose series resulted in substantial increases in humoral antibodies against both the prototype strain and all evaluated variants, similar to or higher than the antibody levels observed in phase 3 studies that were associated with high vaccine efficacy (Dunkle et al., 2022) [1], (Mallory et al., 2022) [4]. These findings, together with the well tolerated safety profile, support use of the recombinant protein vaccine as primary series and booster regimens.
Keywords: COVID-19 Vaccine; Coronavirus; NVX-CoV2373; Protein vaccine safety; SARS-CoV-2; Vaccine benefit/risk; Vaccine efficacy; Vaccine immunogenicity.
. 2023 Sep 20;S0264-410X(23)00871-X.
doi: 10.1016/j.vaccine.2023.07.040. Online ahead of print. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Bethanie Wilkinson[SUP] 1 [/SUP], Kinjal S Patel[SUP] 1 [/SUP], Katherine Smith[SUP] 1 [/SUP], Robert Walker[SUP] 1 [/SUP], Chengbin Wang[SUP] 1 [/SUP], Ann M Greene[SUP] 1 [/SUP], Gale Smith[SUP] 1 [/SUP], Emily R Smith[SUP] 2 [/SUP], Marc Gurwith[SUP] 3 [/SUP], Robert T Chen[SUP] 3 [/SUP]; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG)
Affiliations
- PMID: 37739888
- DOI: 10.1016/j.vaccine.2023.07.040
Novavax, a global vaccine company, began evaluating NVX-CoV2373 in human studies in May 2020 and the pivotal placebo-controlled phase 3 studies started in November 2020; five clinical studies provided adult and adolescent clinical data for over 31,000 participants who were administered NVX-CoV2373. This extensive data has demonstrated a well-tolerated response to NVX-CoV2373 and high vaccine efficacy against mild, moderate, or severe COVID-19 using a two-dose series (Dunkle et al., 2022) [1], (Heath et al., 2021) [2], (Keech et al., 2020) [3], (Mallory et al., 2022) [4]. The most common adverse events seen after administration with NVX-CoV2373 were injection site tenderness, injection site pain, fatigue, myalgia, headache, malaise, arthralgia, nausea, or vomiting. In addition, immunogenicity against variants of interest (VOI) and variants of concern (VOC) was established with high titers of ACE2 receptor-inhibiting and neutralizing antibodies in these studies (EMA, 2022) [5], (FDA, 2023) [6]. Further studies on correlates of protection determined that titers of anti-Spike IgG and neutralizing antibodies correlated with efficacy against symptomatic COVID-19 established in clinical trials (p < 0.001 for recombinant protein vaccine and p = 0.005 for mRNA vaccines for IgG levels) (Fong et al., 2022) [7]. Administration of a booster dose of the recombinant protein vaccine approximately 6 months following the primary two-dose series resulted in substantial increases in humoral antibodies against both the prototype strain and all evaluated variants, similar to or higher than the antibody levels observed in phase 3 studies that were associated with high vaccine efficacy (Dunkle et al., 2022) [1], (Mallory et al., 2022) [4]. These findings, together with the well tolerated safety profile, support use of the recombinant protein vaccine as primary series and booster regimens.
Keywords: COVID-19 Vaccine; Coronavirus; NVX-CoV2373; Protein vaccine safety; SARS-CoV-2; Vaccine benefit/risk; Vaccine efficacy; Vaccine immunogenicity.